Zepbound for Sleep Apnea: What the FDA Approval Means
Tirzepatide (Zepbound) is FDA-approved for obstructive sleep apnea in obesity. Here is the honest picture.
The short answer
In late 2024 the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, the first medication approved for this use. It is meant to be used along with a reduced-calorie diet and more physical activity, and it does not replace CPAP for everyone.
What the trial showed
In the SURMOUNT-OSA program (PMID 38912654), tirzepatide reduced the number of breathing interruptions per hour in adults with obesity and OSA, alongside weight loss. Excess weight is a major driver of OSA, so losing weight can meaningfully improve it.
Ready to start?
$199 Skeptics’ Trial, see if it works for you
One month of medical-grade compounded semaglutide, the $119 doctor review, and a free B-12/lipotropic injection. No long-term commitment.
Start the 30-day trialWhat this does and does not mean
This is a real, FDA-approved indication for the brand drug Zepbound. It does not mean compounded tirzepatide is approved for sleep apnea, it is not. And it does not mean everyone should stop CPAP; that is a decision for your sleep physician. Treating obesity can improve OSA, but the two care teams should coordinate.
How this relates to what we offer
We do not dispense Zepbound and we do not treat sleep apnea with compounded medication. We offer physician-supervised compounded tirzepatide for weight (not FDA-approved or brand-identical), and weight loss itself can help OSA, while your sleep specialist manages the apnea.
What you can start today at New Hope Weight Loss
After a one-time $119 medical review with Dr. Sharma, eligible patients begin physician-supervised compounded semaglutide from $166 a month or compounded tirzepatide from $233 a month, with a $199 one-month Skeptics' Trial. Compounded semaglutide and tirzepatide are prepared by licensed U.S. pharmacies and are not FDA-approved, not brand-identical, and not reviewed by the FDA for safety, effectiveness, or quality. In person in Orange County and by telehealth across California and additional states.
Frequently asked questions
Is Zepbound FDA-approved for sleep apnea?
Yes. In late 2024 the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity, used with diet and activity. It is the first drug approved for this use.
Does compounded tirzepatide treat sleep apnea?
No. The sleep-apnea approval is for the brand drug Zepbound only. Compounded tirzepatide is not FDA-approved for sleep apnea or anything else; it is used for weight under physician supervision.
Can I stop CPAP if I lose weight?
That is a decision for your sleep physician based on a repeat sleep study, not something to do on your own. Weight loss can improve OSA, but care teams should coordinate.
How does weight loss help sleep apnea?
Excess weight is a major driver of obstructive sleep apnea. Losing weight can reduce the number of breathing interruptions, as seen in the SURMOUNT-OSA program (PMID 38912654).
Does New Hope treat sleep apnea?
No. We offer physician-supervised compounded tirzepatide for weight (not FDA-approved or brand-identical). Weight loss can help OSA, but your sleep specialist manages the apnea itself.
This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.